In this review:
Abemaciclib + fulvestrant in HR+/HER2– advanced disease
Palbociclib + letrozole in ER+/HER2– advanced disease
Talazoparib in metastatic disease + a germline BRCA1/2 mutation
Pembrolizumab in heavily pretreated metastatic TNBC
Olaparib active in HER2– metastatic disease + a germline BRCA mutation
Adding pertuzumab to adjuvant trastuzumab + chemotherapy in HER2+ disease
Shorter trastuzumab duration lowers cardiac toxicity
Intermittent vs continuous letrozole: no DFS benefit
Docetaxel/cyclophosphamide x6: non-inferior to ECx4-Tx4 in HER2– early disease
Pembrolizumab improves pCR rates in both TNBC and HR+ disease
ALTTO data: no support for dual anti-HER2 therapy in the adjuvant setting
Please login below to download this issue (PDF)